Mental health experts have welcomed TGA approval of Servier's LATUDA (lurasidone HCl) for the treatment of schizophrenia in adolescents (aged 13-17 years) as “an important therapy” for young patients with what is a debilitating mental illness. …
Latest Video
New Stories
-
New leadership for Bristol-Myers Squibb
October 16, 2018 - - Latest News -
Annual cost of migraine tops $35 billion
October 16, 2018 - - Latest News -
Labor moves to block trade-related PBS changes
October 16, 2018 - - Latest News -
Annual report reveals faster response times
October 16, 2018 - - Latest News -
Lilly's Libby Driscoll: Not 'just another headache'
October 15, 2018 - - Latest News -
The burden of migraine
October 15, 2018 - - Latest News -
Pharmacy backs national consistency on vaccination
October 15, 2018 - - Latest News